Vyome Holdings, Inc
Close on Oct 19, 2026
- Market cap
- $12.91M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 18, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 25, 2026 | During market hours | – | $-0.10 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 29, 2026 | Before market open | $31.59K | $-0.15 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 19, 2025 | During market hours | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | During market hours | $2.30M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | During market hours | $2.00M | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 4, 2024 | Before market open | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 9, 2023 | During market hours | $2.20M | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 7, 2023 | During market hours | $2.30M | – | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 16, 2023 | During market hours | – | – | – |
| Q3 FY2022 Ended Sep 30, 2022 | Nov 14, 2022 | During market hours | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Aug 16, 2022 | After market close | – | – | – |
Press releases
Announcements Vyome filed with the SEC
PRESS RELEASE DATED AUGUST 25, 2026
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE DATED MAY 28, 2026
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE ISSUED FEBRUARY 24, 2026
Material agreement · Other events · EX-99.1 to Form 8-K
VT-1953 PHASE 2 DATA PRESENTATION
Regulation FD disclosure · EX-99.1 to Form 8-K
PRODUCT ASSESSMENT AND VALUATION REPORT
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
PRESS RELEASE ISSUED JANUARY 27, 2026
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
PRESS RELEASE DATED NOVEMBER 18, 2025
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE ISSUED SEPTEMBER 29, 2025
Other events · EX-99.1 to Form 8-K
VYOME THERAPEUTICS INC. AND SUBSIDIARY
Other events · EX-99.1 to Form 8-K
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF VYOME FOR THE QUARTER ENDED JUNE 30, 2025
Other events · EX-99.2 to Form 8-K
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS
Other events · EX-99.3 to Form 8-K
A US-India healthcare platform with clinical-stage immuno-inflammation assets
Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Pricing of $2.6 Million Public Offering
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Vyome Therapeutics, Inc. and Subsidiary
Other events · EX-99.1 to Form 8-K
AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Other events · EX-99.2 to Form 8-K
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Other events · EX-99.3 to Form 8-K
Lifesciences Announces 1-for-25 Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
ReShape Lifesciences® Announces Pricing of
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
A US-India healthcare platform with clinical-stage immuno-inflammation assets
Regulation FD disclosure · EX-99.1 to Form 8-K
ReShape Lifesciences® Reports Third Quarter Ended September 30, 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
ReShape Lifesciences Announces 1-for-58 Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
ReShape Lifesciences® Reports Second Quarter Ended June 30, 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
ReShape Lifesciences® Enters Into Merger Agreement With Vyome Therapeutics
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
ReShape Lifesciences® Enters into Warrant Exercise Transaction for $1.2 Million in Gross Proceeds
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
ReShape Lifesciences® Reports Third Quarter Ended September 30, 2023 Financial Results and 2024 Cost Reduction Plan
Results of operations · EX-99.1 to Form 8-K
Lifesciences ® Announces Pricing of $3.0 Million Public Offering
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Exclusive License Agreement With Biorad Medisys for Obalon ® Gastric Balloon System
Material agreement · Other events · EX-99.1 to Form 8-K
ReShape Lifesciences® Reports Second Quarter Ended June 30, 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
ReShape Lifesciences® Reports First Quarter Ended March 31, 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
ReShape Lifesciences Announces Pricing of $2.5
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Lifesciences Announces Pricing of Upsized
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Lifesciences Announces Closing of Upsized
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
Inc. is a worldwide premier weight-loss solutions company, offering an integrated portfolio of proven products and services that manage
Other events · EX-99.1 to Form 8-K
ReShape Lifesciences Announces 1-for-50 Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
ReShape Lifesciences™ Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Lifesciences Announces $750,000 Registered Direct Offering
Material agreement · Unregistered share sale · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
ReShape Lifesciences™ Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K